BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10097241)

  • 1. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am Heart J; 1999 Apr; 137(4 Pt 2):S9-S13. PubMed ID: 10097241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin in the treatment and prevention of cardiovascular disease.
    Gaziano JM; Skerrett PJ; Buring JE
    Haemostasis; 2000; 30 Suppl 3():1-13. PubMed ID: 11182624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of cardiovascular disease: risks and benefits of aspirin.
    Buring JE; Hennekens CH
    J Gen Intern Med; 1990; 5(5 Suppl):S54-7. PubMed ID: 2231066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on aspirin in the primary prevention of cardiovascular disease.
    Eidelman RS; Hebert PR; Weisman SM; Hennekens CH
    Arch Intern Med; 2003 Sep; 163(17):2006-10. PubMed ID: 14504112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions.
    Hennekens CH
    Curr Atheroscler Rep; 2007 Nov; 9(5):409-16. PubMed ID: 18001625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin in chronic cardiovascular disease and acute myocardial infarction.
    Hennekens CH
    Clin Cardiol; 1990 Mar; Suppl 5():V62-6; discussion V67-72. PubMed ID: 2182244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
    Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL
    JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Annu Rev Public Health; 1997; 18():37-49. PubMed ID: 9143711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
    Bartolucci AA; Howard G
    Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin.
    Bartolucci AA; Tendera M; Howard G
    Am J Cardiol; 2011 Jun; 107(12):1796-801. PubMed ID: 21481826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin in the primary prevention of cardiovascular disease: current knowledge and future research needs.
    Hennekens CH; Dalen JE
    Trends Cardiovasc Med; 2014 Nov; 24(8):360-6. PubMed ID: 25444455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
    JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
    Aronow WS
    Drugs Aging; 1999 Aug; 15(2):91-101. PubMed ID: 10495069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
    Berger JS; Krantz MJ; Kittelson JM; Hiatt WR
    JAMA; 2009 May; 301(18):1909-19. PubMed ID: 19436018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The aspirin controversy in primary prevention.
    Raju NC; Eikelboom JW
    Curr Opin Cardiol; 2012 Sep; 27(5):499-507. PubMed ID: 22874127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators.
    Yasue H; Ogawa H; Tanaka H; Miyazaki S; Hattori R; Saito M; Ishikawa K; Masuda Y; Yamaguchi T; Motomiya T; Tamura Y
    Am J Cardiol; 1999 May; 83(9):1308-13. PubMed ID: 10235086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose aspirin for primary prevention of cardiovascular disease.
    Bredie SJ; Wollersheim H; Verheugt FW; Thien T
    Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.